Bal Pharma's Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Bal Pharma Ltd reported a 17.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.5%.
- Its expenses for the quarter were up by 15.9% QoQ and 17.9% YoY.
- The net profit increased 148.6% QoQ and increased 244.2% YoY.
- The earnings per share (EPS) of Bal Pharma Ltd stood at 1.12 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 88.02 | 75.14 | 73.66 | 17.1% | 19.5% |
Total Expenses | 86.22 | 74.42 | 73.10 | 15.9% | 17.9% |
Profit Before Tax | 1.79 | 0.72 | 0.57 | 148.6% | 214.0% |
Tax | 0.00 | 0.00 | 0.05 | - | -100.0% |
Profit After Tax | 1.79 | 0.72 | 0.52 | 148.6% | 244.2% |
Earnings Per Share | 1.12 | 0.45 | 0.33 | 148.9% | 239.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bal Pharma Ltd is a pharmaceutical company that operates in the healthcare industry. The company primarily focuses on the development, manufacturing, and distribution of pharmaceutical products. Its product portfolio includes a wide range of generics, branded formulations, and active pharmaceutical ingredients (APIs). Bal Pharma serves both domestic and international markets, providing medications that cater to various therapeutic segments. However, specific details about recent major developments or strategic initiatives are not available from the provided data.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Bal Pharma Ltd reported a total income of ₹88.02 crores. This represents a sequential increase of 17.1% compared to the second quarter of fiscal year 2026 (Q2FY26), where total income stood at ₹75.14 crores. On a year-over-year basis, total income grew by 19.5% from ₹73.66 crores in the third quarter of fiscal year 2025 (Q3FY25). These figures reflect a solid growth trajectory in revenue generation over the observed periods.
Profitability
During Q3FY26, Bal Pharma Ltd achieved a profit before tax of ₹1.79 crores, marking a significant improvement of 148.6% from Q2FY26, where the profit before tax was ₹0.72 crores. Compared to Q3FY25, the profit before tax grew by 214.0% from ₹0.57 crores. The company reported a profit after tax of ₹1.79 crores in Q3FY26, up by 148.6% quarter-over-quarter and 244.2% year-over-year. Additionally, the earnings per share increased to ₹1.12 in Q3FY26 from ₹0.45 in Q2FY26 and ₹0.33 in Q3FY25, showcasing a marked growth in shareholder value.
Operating Metrics
Bal Pharma Ltd's total expenses in Q3FY26 were ₹86.22 crores, which is a 15.9% increase from Q2FY26's total expenses of ₹74.42 crores. Year-over-year, total expenses rose by 17.9% from ₹73.10 crores in Q3FY25. The company did not incur any tax expenses in Q3FY26 or Q2FY26, whereas a tax of ₹0.05 crores was recorded in Q3FY25. The growth in total income outpaced the increase in total expenses, contributing to the improved profitability metrics for the quarter.